Madrigal Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization10,474 mln

Float21.53 mln

Earnings Date11/03/2026

Piotroski F-Score

2 / 9

Weak

Beneish M-Score

-0.09

Highly suspicious

1-Year Forecast

685.22

Exceptional upside

Relative Strength

28 / 100

Underperforming

Debt / Equity

0.66

Moderate leverage

Pre-Tax Margin

-25%

Deeply loss-making

Business Description

Madrigal Pharmaceuticals is a US-based drug developer dedicated to treating a serious liver disease caused by metabolic disorders. Its flagship product, Rezdiffra, works by targeting specific receptors in the liver to address the condition. Founded in 2016 and based in West Conshohocken, Pennsylvania, the company remains focused on expanding treatment options for patients with this underserved disease.

Key Fundamentals

EPS-12.85

ROE-54.34

RPS56.15

ROIC-406

ROA-26.61

Interest Cover-10.24

EBITDA, mln-292

EV / EBITDA-49.64

EV / EBIT-49.39

Revenue, mln1,284

EV / Revenue11.29

Quote Details

Last 434.24

Change -19.1 (-4.21%)

Open 453.55

Volume 234,833

Turnover 101,973,880

Average Volume 292,908

Financial Ratios

Pre-Tax Profit Margin-25

Leverage Ratio2.38

Current Ratio3.21

Price / Book22.41

Price / Tangible Book22.72

Debt / Equity0.66

Price / Sales10.16

Financial Strength

Altman Z-Score8.32

Piotroski F-Score 2 / 9

Beneish M-Score-0.09

1-Year Target Price685.22

Short Ratio10.83

Short % of Float12.19

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-3.45%	21 / 100
1 Month	-15.39%	23 / 100
2 Months	-18.94%	23 / 100
6 Months	-15.25%	29 / 100
1 Year	4.4%	56 / 100